SOURCE: CannaPharmaRx, Inc.

CannaPharmaRx, Inc. Logo

April 13, 2015 13:56 ET

CannaPharmaRx, Inc. Engages Viridian Capital & Research

CARNEYS POINT, NJ--(Marketwired - April 13, 2015) - CannaPharmaRx, Inc. (OTCQB: CPMD), an early stage pharmaceutical company whose purpose is to advance cannabinoid research and discovery, is pleased to announce that it has recently engaged Viridian Capital & Research, LLC for financial, investor relations and corporate advisory services.

CannaPharmaRx is an early-stage pharmaceutical company whose purpose is to advance cannabinoid research and discovery using proprietary formulation and drug delivery technology currently in development. The Company is currently focused on targeting disease states where its delivery systems can have optimal impact with therapeutic differentiation among alternative cannabinoid therapies, including: neurological disorders, oncology, infectious disease, pain management, inflammatory disease, gastrointestinal disorders and ophthalmology.

Mr. Gerry Crocker, CannaPharmaRx's CEO, commented, "As we build CannaPharmaRx into a world class company, we decided to engage an expert advisor that can not only help to bring us capital and visibility within the investment community, but also the expertise to optimize our corporate structure and strategy in order to accelerate our growth. This is why we chose to engage Viridian Capital & Research."

Mr. Scott Greiper, President of Viridian Capital & Research, stated, "The impressive track record of the CannaPharmaRx team and its mission to advance cannabinoid research and discovery using proprietary formulation and drug delivery technology currently in development provides a significant opportunity for growth. We are thrilled to have the opportunity to help support the growth of this Company." 

About CannaPharmaRx, Inc.
CannaPharmaRx, Inc. is an early-stage pharmaceutical company whose purpose is to advance cannabinoid research and discovery using proprietary formulation and drug delivery technology currently in development. Cannabinoids are a class of chemicals that, once ingested, are active in humans and animals through the "endocannabinoid system" -- one of the most widely expressed systems of receptors in the human body. CannaPharmaRx is currently focused on targeting disease states where its delivery systems can have optimal impact with therapeutic differentiation among alternative cannabinoid therapies, including: neurological disorders, oncology, infectious disease, pain management, inflammatory disease, gastrointestinal disorders and ophthalmology. For more information, please visit www.CannaPharmaRx.com.

About Viridian Capital & Research, LLC
Viridian Capital & Research, LLC is a specialized boutique banking and strategic advisory firm that provides research, investment banking, investor relations and corporate development services to emerging growth companies in the cannabis sector. Our banking practice, through broker-dealer Pickwick Capital Partners, provides capital and M&A to fund the growth of our clients, while our advisory practice helps to position and build their business. Leveraging our team's decades of high level operating and transactional experience on Wall Street, in industry and in the government, we provide flexible comprehensive strategic and financial solutions that assist cannabis enterprises in realizing their full potential. For more information, please visit http://www.viridiancr.com.

Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated," and "intend" among others. These forward-looking statements are based on CannaPharmaRx's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to: substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; clinical trials involving a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical products under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. CannaPharmaRx does not undertake any obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in CannaPharmaRx's Annual Report on Form 10-K for the year ended December 31, 2014 and other periodic reports filed with the Securities and Exchange Commission.

Contact Information

  • Contact:

    Investor Relations for Viridian Capital & Research:
    Michael Swartz
    Analyst
    Viridian Capital & Research, LLC
    212-333-0257
    mswartz@viridiancr.com

    Investor Relations for CannaPharmaRx:
    Bridamary Rosario
    856-376-0500
    bbrosario@cannapharmarx.com